Parameters critical for the effector mechanism of anti-CD20 antibodies revisited

被引：1
|
作者：
Stasilojc, Grzegorz [1 ]
Felberg, Anna [1 ]
Okroj, Marcin [1 ]
机构：
[1] Univ Gdansk, Intercollegiate Fac Biotechnol, Dept Med Biotechnol, Gdansk, Poland
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 180卷 / 06期
关键词：
anti-CD20; antibodies; hybridoma formation; MONOCLONAL-ANTIBODIES; CD20; RITUXIMAB; EFFICACY; IMMUNOTHERAPY; CYTOTOXICITY; MALIGNANCIES; COMPLEMENT; RESISTANCE; THERAPY;
D O I：
10.1111/bjh.15130
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：777 / 779
页数：3
相关论文
共 50 条
  • [21] Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies
    Tipton, Thomas R. W.
    Roghanian, Ali
    Oldham, Robert J.
    Carter, Matthew J.
    Cox, Kerry L.
    Mockridge, C. Ian
    French, Ruth R.
    Dahal, Lekh N.
    Duriez, Patrick J.
    Hargreaves, Philip G.
    Cragg, Mark S.
    Beers, Stephen A.
    [J]. BLOOD, 2015, 125 (12) : 1901 - 1909
  • [22] Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus
    Shah, Kavina
    Cragg, Mark
    Leandro, Maria
    Reddy, Venkat
    [J]. BIOLOGICALS, 2021, 69 : 1 - 14
  • [23] Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children
    Ravani, Pietro
    Bonanni, Alice
    Rossi, Roberta
    Caridi, Gianluca
    Ghiggeri, Gian Marco
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 11 (04): : 710 - 720
  • [24] Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity
    Rossi, Edmund A.
    Chang, Chien-Hsing
    Cardillo, Thomas M.
    Stein, Rhona
    Pilas, Diana
    Nordstrom, Diane L.
    Kopinski, John
    Goldenberg, David M.
    [J]. BLOOD, 2008, 112 (11) : 564 - 565
  • [25] Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
    Cragg, MS
    Glennie, MJ
    [J]. BLOOD, 2004, 103 (07) : 2738 - 2743
  • [26] Anti-CD20 in lupus
    Isenberg, DA
    Leandro, MJ
    Ehrenstein, MR
    Edwards, JCW
    Manson, J
    Cambridge, G
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 27 - 28
  • [27] Anti-CD20 monoclonal antibodies: Beyond B-cells
    Avivi, Irit
    Stroopinsky, Dina
    Katz, Tamar
    [J]. BLOOD REVIEWS, 2013, 27 (05) : 217 - 223
  • [28] Treatment of posttransplantation diabetes mellitus with anti-CD20 monoclonal antibodies
    Vandenbosch, K
    Champagne, MA
    Gonthier, M
    Moghrabi, A
    Vachon, MF
    Duval, M
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 64 - 64
  • [29] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
    Finn Sellebjerg
    Morten Blinkenberg
    Per Soelberg Sorensen
    [J]. CNS Drugs, 2020, 34 : 269 - 280
  • [30] Challenges of initiating anti-CD20 monoclonal antibodies in RR MS
    de la Motte, M. Boudot
    Louapre, C.
    Papeix, C.
    Lubetzki, C.
    Maillart, E.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 44 - 44
12345